Extension Study in a Cohort of Adult Patients With SARS-CoV-2 Infection Requiring Hospital Admission and Received Treatment With Plitidepsin in the APLICOV-PC Study
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs Plitidepsin (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms E-APLICOV-PC
- Sponsors PharmaMar
- 21 Mar 2022 Status changed from active, no longer recruiting to completed.
- 10 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2022 Planned End Date changed from 1 May 2022 to 1 Jun 2022.